Access Vascular
Bedford, US · Founded 2015 · Delaware corporation · 3 known investors
Access Vascular develops thrombus-evading intravascular catheters made from a proprietary biomaterial, offering an FDA-cleared PICC and the HydroMID peripherally inserted midline catheter to reduce vascular access complications. The company designs and manufactures its medical devices for clinical use in the United States.
Founders & leadership
Access Vascular was founded in 2015 by James Biggins.
JB
James BigginsChief Executive Officer, President and Founder
PS
Paul SabinNamed on SEC filing
JP
Joseph PellegrinoNamed on SEC filing
BR
Brent RatzNamed on SEC filing
DB
Dennis ByrneChief Commercial Officer
SB
Scott BloodVP of Regulatory and Quality
KM
Katie MotherwayVP of Human Resources
AD
Aaron DynesController
Investors · 3
Reported raises · per SEC filings
Form D private placements$51.8M disclosed across 5 of 6 rounds · 2017–2023
▶$20.6MraisedOct 2023 · 19 investors · BiotechnologyRule 506(b)
▶$20.6MraisedOct 2023 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JJ PelligrinoDirector
- Amine BentalebDirector
- James BigginsExecutive Officer
- Luc MarengereDirector
- Michael R JaffDirector
- Marc RiviereDirector
- Brent SabinDirector
- Offering amount
- $31.6M
- Amount sold
- $20.6M
- Minimum investment
- $8K
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MofferedOct 2022 · 2 investors · BiotechnologyRule 506(b)
▶$10MofferedOct 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Luc MarengereDirector
- Brent SabinDirector
- James BigginsExecutive Officer
- JJ PelligrinoDirector
- Michael R JaffDirector
- Marc RiviereDirector
- Amine BentalebDirector
- Offering amount
- $10M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$19.9MraisedMar 2021 · 14 investors · BiotechnologyRule 506(b)
▶$19.9MraisedMar 2021 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JJ PelligrinoDirector
- Paul SabinDirector
- Brent RatzDirector
- James BigginsExecutive Officer
- Michael R JaffDirector
- Amine BentalebDirector
- Luc MarengereDirector
- Alexandra MacLeanDirector
- Offering amount
- $19.9M
- Amount sold
- $19.9M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.6MraisedSep 2019 · 15 investors · BiotechnologyRule 506(b)
▶$5.6MraisedSep 2019 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul SabinDirector
- James BigginsExecutive Officer
- JJ PelligrinoDirector
- Brent RatzDirector
- Offering amount
- $7.3M
- Amount sold
- $5.6M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1.9MraisedMay 2018 · 7 investors · BiotechnologyRule 506(b)
▶$1.9MraisedMay 2018 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brent RatzDirector
- Paul SabinDirector
- Joseph PellegrinoDirector
- James BigginsExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $1.9M
- Minimum investment
- $25K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$3.8MraisedAug 2017 · 25 investors · BiotechnologyRule 506(b)
▶$3.8MraisedAug 2017 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul SabinDirector
- Joseph PellegrinoDirector
- James BigginsExecutive Officer, Director
- Brent RatzDirector
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- Minimum investment
- $15K
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapivWatch149 shared keywordsivWatch makes a continuous IV monitoring system that detects IV infiltrations and extravasations early, alerting clinical teams even when physical signs are not visible. The device is aimed at hospitals and care teams to support patient assessment protocols and reduce negative patient events.
Medbridge148 shared keywordsMedbridge offers a healthcare software platform combining evidence-based online continuing education, patient care tools (including home exercise programs and remote therapeutic monitoring), and outcomes analytics. It serves clinicians and healthcare providers—from individual practitioners and physical therapists to large health systems—to support staff development and patient care.
Companies competing with Access Vascular for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Access Vascular do?
- Access Vascular develops thrombus-evading intravascular catheters made from a proprietary biomaterial, offering an FDA-cleared PICC and the HydroMID peripherally inserted midline catheter to reduce vascular access complications. The company designs and manufactures its medical devices for clinical use in the United States.
- Who founded Access Vascular?
- Access Vascular was founded by James Biggins in 2015.
- Who are Access Vascular's investors?
- Access Vascular's investors include TVM Capital Life Science, Green Park & Golf Ventures, TVM Capital.
- How much funding has Access Vascular raised?
- Access Vascular has disclosed $51.8M raised across 5 of its 6 known rounds.
- Where is Access Vascular headquartered?
- Access Vascular is headquartered in Bedford, US.